The NCI cohort consists of 30 companies chosen through a rigorous peer review process involving over 70 investors and strategic partners. Myosin’s inclusion marks a milestone for its lead asset, MT-125, a first-in-class, brain-penetrant dual non-muscle myosin inhibitor. The drug is currently undergoing a Phase 1/2 trial known as STAR-GBM and has already secured FDA Fast Track and Orphan Drug designations for glioblastoma treatment.

CEO Courtney Miller noted that the NCI has served as a consistent partner during the development of MT-125. Beyond this lead program, the company is advancing MT-110, an NIH-supported, IND-stage asset targeting CNS disorders. Inclusion in the showcase grants Myosin direct access to investor networks and a feature in the NCI’s 2026–2027 Companies Book, further validating their platform’s potential to address both solid and hematologic malignancies.